Relationship of activated extracellular signal-regulated kinase 1/2 with lung metastasis in salivary adenoid cystic carcinoma

Oncology Reports

Volumn 21, Issue 1, 2009, Pages 137-143

  Hu, Kai ^a   Gan, Ye Hua ^a   Li, Sheng Lin ^a   Gao, Yan ^a   Wu, Deng Cheng ^a   Wang, Cun Yu ^b   Yu, Guang Yan ^a  

^a PEKING UNIVERSITY SCHOOL AND HOSPITAL OF STOMATOLOGY   (China)

^b UCLA SCHOOL OF DENTISTRY   (United States)

Author keywords

Extracellular signal regulated kinase 1 2; Invasion; Metastasis; Migration; Salivary adenoid cystic carcinoma

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ENZYME INHIBITOR;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA; ADOLESCENT; CELL MOTION; DRUG EFFECT; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; SALIVARY GLAND TUMOR; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; BLOTTING, WESTERN; CARCINOMA, ADENOID CYSTIC; CELL MOVEMENT; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; SALIVARY GLAND NEOPLASMS;

EID: 61449307054     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000200     Document Type: Article

References (33)

1. Szanto PA, Luna MA, Tortoledo E and White RA: Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer 54: 1062-1069, 1984.
2. Zhang J, Peng B and Chen X: Expressions of nuclear factor kappa B, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res 11: 7334-7343, 2005.
3. Huang M, Ma D, Sun K, Yu G, Guo C and Gao F: Factors influencing survival rate in adenoid cystic carcinoma of the salivary glands. Int J Oral Maxillofac Surg 26: 435-439, 1997.
4. Sung MW, Kim KH, Kim JW, et al: Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 129: 1193-1197, 2003.
5. Gupta GP and Massague J: Cancer metastasis: Building a framework. Cell 127: 679-695, 2006.
6. Rapidis AD, Givalos N, Gakiopoulou H, et al: Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature. Oral Oncol 41: 328-335, 2005.
7. Li SL, Liu XP and Zhang KH: Establishment of a human cancer cell line from adenoid cystic carcinoma of the minor salivary gland. Zhonghua Kou Qiang Yi Xue Za Zhi 25: 29-31, 1990.
8. Reddy KB, Nabha SM and Atanaskova N: Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22: 395-403, 2003.
9. Krueger JS, Keshamouni VG, Atanaskova N and Reddy KB: Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 20: 4209-4218, 2001.
10. Giehl K: Oncogenic Ras in tumour progression and metastasis. Biol Chem 386: 193-205, 2005.
11. Hoshino R, Chatani Y, Yamori T, et al: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822, 1999.
12. Sivaraman VS, Wang H, Nuovo GJ and Malbon CC: Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478-1483, 1997.
13. Salh B, Marotta A, Matthewson C, Ahluwalia M, Flint J, Owen D and Pelech S: Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. Anticancer Res 19: 731-740, 1999.
14. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F and Eppenberger U: Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 89: 384-388, 2000.
15. Mercer KE and Pritchard CA: Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta Rev Cancer 1653: 25-40, 2003.
16. Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH and Murphy LC: Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 8: 1747-1753, 2002.
17. Gioeli D, Mandell JW, Petroni GR, Frierson HF and Weber MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284, 1999.
18. Zeng QH, Chen SQ, You ZB, Yang F, Carey TE, Saims D and Wang CY: Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NF kappa B. J Biol Chem 277: 25203-25208, 2002.
19. Hu JA: Blockade of the ERK pathway down-regulation MMPS in adenoid cystic carcinoma. J Oral Pathol Med 35: 428, 2006.
20. Handra-Luca A, Bilal H, Bertrand JC and Fouret P: Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma - Association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol 163: 957-967, 2003.
21. Lauffenburger DA and Horwitz AF: Cell migration: A physically integrated molecular process. Cell 84: 359-369, 1996.
22. Hartmann G, Weidner KM, Schwarz H and Birchmeier W: The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of Ras. J Biol Chem 269: 21936-21939, 1994.
23. Klemke RL, Yebra M, Bayna EM and Cheresh DA: Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin. J Cell Biol 127: 859-866, 1994.
24. Vial E, Sahai E and Marshall CJ: ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4: 67-79, 2003.
25. Overall CM and Lopez-Otin C: Strategies for mmp inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657-672, 2002.
26. Ree AH, Bjornland K, Brunner N, Johansen HT, Pedersen KB, Aasen AO and Fodstad O: Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells. Clin Exp Metastasis 16: 205-215, 1998.
27. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
28. Hu K, Li SL, Gan YH, Wang CY and Yu GY: Epiregulin promotes migration and invasion of salivary adenoid cystic carcinoma cell line SACC-83 through activation of ERK and Akt. Oral Oncol (In press).
29. Katz M, Amit I and Yarden Y: Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta Mol Cell Res 1773: 1161-1176, 2007.
30. Shelly M, Pinkas-Kramarski R, Guarino BC, et al: Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem 273: 10496-10505, 1998.
31. Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM and Theodorescu D: Profiling the evolution of human metastatic bladder cancer. Cancer Res 64: 7813-7821, 2004.
32. Gupta GP, Nguyen DX, Chiang AC, et al: Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446: 765-770, 2007.
33. Draper BK, Komurasaki T, Davidson MK and Nanney LB: Epiregulin is more potent than EGF or TGFalpha in promoting in vitro wound closure due to enhanced ERK/MAPK activation. J Cell Biochem 89: 1126-1137, 2003.